Technical Analysis for CYTH - Cyclo Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 1.30 | 0.78% | 0.01 |
CYTH closed down 0.77 percent on Thursday, April 25, 2024, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.78% | |
| Narrow Range Bar | Range Contraction | 0.78% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 7.44% | |
| Inside Day | Range Contraction | 7.44% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 3.17% | |
| Stochastic Buy Signal | Bullish | 3.17% | |
| Pocket Pivot | Bullish Swing Setup | 3.17% | |
| Lower Bollinger Band Walk | Weakness | 3.17% | |
| Gapped Up | Strength | 3.17% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | 3 minutes ago |
| 60 Minute Opening Range Breakdown | 19 minutes ago |
| 60 Minute Opening Range Breakout | 37 minutes ago |
| Rose Above 20 DMA | about 1 hour ago |
| Rose Above Previous Day's High | about 1 hour ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. The company is planning an early phase clinical trial using Trappsol Cyclo intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease. Additional indications for the active ingredient in Trappsol Cyclo are in development.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Rare Diseases Alzheimer's Disease Lipid Storage Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Rare Diseases Alzheimer's Disease Lipid Storage Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.57 |
| 52 Week Low | 0.84 |
| Average Volume | 107,561 |
| 200-Day Moving Average | 1.47 |
| 50-Day Moving Average | 1.49 |
| 20-Day Moving Average | 1.31 |
| 10-Day Moving Average | 1.24 |
| Average True Range | 0.12 |
| RSI (14) | 44.44 |
| ADX | 17.54 |
| +DI | 16.64 |
| -DI | 21.98 |
| Chandelier Exit (Long, 3 ATRs) | 1.44 |
| Chandelier Exit (Short, 3 ATRs) | 1.45 |
| Upper Bollinger Bands | 1.48 |
| Lower Bollinger Band | 1.14 |
| Percent B (%b) | 0.44 |
| BandWidth | 25.82 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0091 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.35 | ||||
| Resistance 3 (R3) | 1.35 | 1.33 | 1.34 | ||
| Resistance 2 (R2) | 1.33 | 1.31 | 1.33 | 1.34 | |
| Resistance 1 (R1) | 1.31 | 1.31 | 1.32 | 1.31 | 1.33 |
| Pivot Point | 1.29 | 1.29 | 1.30 | 1.29 | 1.29 |
| Support 1 (S1) | 1.27 | 1.27 | 1.28 | 1.27 | 1.25 |
| Support 2 (S2) | 1.25 | 1.27 | 1.25 | 1.24 | |
| Support 3 (S3) | 1.23 | 1.25 | 1.24 | ||
| Support 4 (S4) | 1.23 |
